Tazeen Ahmad, an analyst from Bank of America Securities, maintained the Buy rating on Ascendis Pharma (ASND – Research Report). The associated price target remains the same with $192.00.
Tazeen Ahmad’s rating is based on the promising initial demand for Ascendis Pharma’s Yorvipath, as indicated by a survey of endocrinologists. The survey revealed a strong uptake, with a significant number of scripts written for uncontrolled HPT patients since the product’s launch. This suggests a positive reception among healthcare professionals, which could drive further adoption.
Moreover, the early payor coverage dynamics are encouraging, with a high percentage of patients receiving the drug through insurance. This coverage is crucial for the product’s success, and while there are still uncertainties regarding payor stances for well-controlled HPT patients, the potential for expanded usage in this population presents additional upside. The combination of these factors supports the Buy rating with a price objective of $192.
According to TipRanks, Ahmad is an analyst with an average return of -6.7% and a 41.15% success rate. Ahmad covers the Healthcare sector, focusing on stocks such as Sarepta Therapeutics, Vertex Pharmaceuticals, and Ascendis Pharma.